The announcement marks the second FDA designation for ATSN-201, which previously received Rare Pediatric Disease designation.

According to the company, topline results will be presented at the 2024 American Academy of Ophthalmology Annual Meeting, ...

The report urges the US Department of Health and Human Services, in collaboration with departments of education at the state ...

Unlocking the potential of donor scleral tissue: Innovations and future applications. When organs are donated, it is with the ...

The acquisition strengthens the company’s rare disease segment, and adds 2 durable commercial assets, Iluvien and Yutiq with ...

David A. Eichenbaum, MD, presented key data from two clinical trials focusing on therapies for age-related macular ...

Diana Do, MD, spoke with the Ophthalmology Times team about her presentation at the Retina Society meeting focusing on Population Pharmacokinetic Modeling and Simulation of Ocular Clearance for ...

Laura M. Periman, MD, shares her passion for dry eye disease, discussing her discovery of the Alpenglow Sign in Demodex ...

Researchers at the Karolinska Institute continue to investigate whether gene therapy can improve vision in people with ...

The American Society of Retina Specialists (ASRS) hosted its annual meeting July 17 to 20 in the Swedish capital city of ...

Durga Borkar, MD, sat down with Sydney Crago of Modern Retina to discuss one of her presentations on the first time phase 2 ...

The authors concluded that the switch from aflibercept biosimilar ranibizumab in patients with nAMD demonstrated efficacy in ...